

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 June 2021 (17.06.2021)



(10) International Publication Number
WO 2021/119128 A1

(51) International Patent Classification:

C07K 14/71 (2006.01) A61P 37/06 (2006.01)
C07K 16/28 (2006.01) A61K 39/395 (2006.01)

(21) International Application Number:

PCT/US2020/064010

(22) International Filing Date:

09 December 2020 (09.12.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/945,842 09 December 2019 (09.12.2019) US
63/110,111 05 November 2020 (05.11.2020) US

(71) Applicant: SYNDAX PHARMACEUTICALS, INC.

[US/US]; 35 Gatehouse Drive, Building D, Floor 3,
Waltham, Massachusetts 02451 (US).

(72) Inventors: ORDENTLICH, Peter; 28 Slocum Road, Lex-

ington, Massachusetts 02421 (US). MEYERS, Michael; 6
Summit Street, Hasting-on-Hudson, New York 10706 (US).
MORRISON, Briggs W.; 14 Rittenhouse Circle, Newton,
Pennsylvania 18940 (US).

(74) Agent: OWENS, Eric A. et al.; 1299 Pennsylvania Ave-
nue, NW, Suite 700, Washington, District of Columbia
20004 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: ANTIBODIES FOR THE TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE

Axatilimab PK and circulating monocyte pharmacodynamic changes




FIG. 7

(57) Abstract: The present invention relates to methods of treating sclerotic conditions and more specifically to methods of treating chronic graft versus host disease with specific dosages of an anti-CSF-1R antibody, specifically axatilimab.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*